Gater Deborah
Thomson Reuters, London, UK.
IDrugs. 2010 Aug;13(8):514-6.
The 32nd National Medicinal Chemistry Symposium, held in Minneapolis, MN, USA, included topics covering new developments in the field of medicinal chemistry. This conference report highlights selected presentations on NR2B subtype-selective NMDA receptor antagonists from Merck; selective neuronal nitric oxide synthase inhibitors from Northwestern University; novel GPR119 agonists, suchas GSK-1292263A (GlaxoSmithKline plc), PSN-821 ((OSI) Prosidion) and MBX-2982 (Metabolex Inc); a small-molecule Bcl inhibitor,navitoclax (Abbott Laboratories); and p53-targeting agents from sanofi-aventis and Ascenta Therapeutics Inc, including AT-219.
第32届全国药物化学研讨会在美国明尼苏达州明尼阿波利斯市举行，会议主题涵盖了药物化学领域的新进展。本会议报告重点介绍了以下精选报告：默克公司的NR2B亚型选择性NMDA受体拮抗剂；西北大学的选择性神经元型一氧化氮合酶抑制剂；新型GPR119激动剂，如GSK - 1292263A（葛兰素史克公司）、PSN - 821（（OSI）普洛西迪恩公司）和MBX - 2982（美达博医药公司）；小分子Bcl抑制剂维托克洛克斯（雅培实验室）；以及赛诺菲 - 安万特公司和Ascenta Therapeutics公司的p53靶向药物，包括AT - 219。
